Anthem Biosciences Q2 FY27 Earnings Call: Sees FY26-Level Margins Sustainable, Rs. 1,200 Cr Unit 4 Capex Intact

Anthem Biosciences Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Quarter, But a Slow Q1 Still Weighs on H1

• Q2 FY 2026-2027 revenue of Rs.594 Cr — CRDMO contributed Rs.509 Cr and specialty ingredients Rs.85 Cr; revenue grew 8% YoY, with currency range-bound at 94.5–96.5 through the quarter (company reports only in rupee terms, no CC tracking).
• Q2 EBITDA at Rs.330 Cr (50.6% margin) — includes other income of Rs.59 Cr (vs Rs.48 Cr in Q2 FY26); PBT Rs.296 Cr; PAT Rs.211 Cr at 32.04% margins.
• H1 FY 2026-2027 revenue of Rs.1,012 Cr — CRDMO Rs.850 Cr, specialty ingredients Rs.162 Cr; EBITDA Rs.506 Cr (46.2% margin, incl. Rs.84 Cr other income); PAT Rs.331 Cr at 30.2%.
• Margin expansion attributed to operating leverage — CFO cited a sizable Q2 revenue ramp on a broadly flat cost base versus a low Q1 FY 2026-2027, plus cost discipline, yield optimization and workforce productivity.
• Analyst flagged ~7% revenue degrowth in 1H FY 2026-2027 — management acknowledged "a lot of catching up to do" after slow Q1, with further catch-up expected in Q3 FY 2026-2027 and Q4 FY 2026-2027.
• Net cash of Rs.1,530 Cr as of 30 Sep 2026 — balance sheet remains debt-free ahead of the heavy Unit 4 capex cycle.

FY26-Level Margins Sustainable; ~50% Not Committed

• Q2 EBITDA margin of ~50% vs ~43% in FY 2025-2026 — management said FY26-level margins (~43%, incl. other income) are "definitely sustainable" in FY 2026-2027, but explicitly declined to commit to the ~50% printed in Q2.
• Gross margin up ~3% in Q2 FY 2026-2027 — attributed to reduced reliance on Chinese sourcing, complete in-house manufacturing, and product/customer mix.
• No full-year FY 2026-2027 revenue number given — CFO said "double digit growth definitely we'll try to deliver," and affirmed full-year YoY growth would be majority ex-currency, as no significant FX benefit is assumed for the topline in FY 2026-2027.
• CFO "very confident" of FY 2026-2027 EBITDA and PAT growth — citing the company's superior margin profile; CEO called margins "sufficiently high."
• Specialty ingredients targeted at ~20% of sales by end of FY 2026-2027 — positioned as a backstop against CRDMO project lumpiness; segment revenue was flat in Q2, consistent with the historical pattern of strong CDMO quarters coinciding with muted specialty ingredients performance. Segment-level margin splits are not disclosed, but management stated specialty margins are as profitable as the rest of the business.

15th Commercial Molecule Approved; Long Patent Runway

• Commercial molecules rose from 14 to 15 in Q2 FY 2026-2027 — late-stage count declined from 10 to 9 as one program received commercial approval; the new molecule is from the emerging biotech portfolio in chronic care, with indication and peak sales undisclosed for confidentiality reasons.
• First patent expiries begin in 2032 — extending to 2037 and almost 2040; most of the ~10 older commercialized molecules (per Nomura's Sayan Mukherjee) are yet to reach peak sales, leaving substantial headroom.
• New pipeline peak sales aggregate ~$10 billion (period unspecified) — per-molecule estimates range from $1 billion to $4–5 billion; on an averaging-out basis, per-molecule revenue is expected to be similar to the existing revenue base (~$12 million benchmark cited by the analyst).
• Indication expansion could lift economics — one or two new molecules address very large, high-dosage indications; some orphan-launch drugs have 2–3 additional indications in trials, with approvals possible within Q3–Q4 FY 2026-2027.
• Five molecules commercialized over the last 18 months — an equal mix of APIs and advanced intermediates, expected to contribute meaningfully over the next 3–4 years; several were recently acquired by big pharma, with Anthem as sole supplier (no tech transfer executed), though management acknowledged a second supplier will likely emerge over time.
• Of the 9 late-phase projects, trial outcomes due over 18–24 months — a few could go commercial in FY 2026-2027 itself, though timing is variable and outside Anthem's control, with Phase 3 failure risk flagged.

Europe-Heavy Shipping, Biotech-Led Book, China De-Risked

• ~84% international / ~16% India domestic revenue mix — within exports, US ~22–24%, Europe ~60%, ROW ~1–2%; management clarified Europe is a shipping destination while customer origin is global big pharma, and no geography-level growth split is tracked.
• Business split ~85% CDMO / ~15% specialty ingredients — within CDMO, 65% is commercial manufacturing of approved molecules, with the balance 20% split equally between R&D and development supplies.
• Customer concentration is high — top 5 customers ~50% of business; top 10 ~80%.
• China sourcing largely removed — the Chinese vendor reliance flagged in the DRHP has been mostly eliminated over ~18 months; on an H1 FY 2026-2027 basis, ~75–78% of procurement is domestic and China ~20–21%, with captive domestic vendors being developed for starting materials.
• 8–9 big pharma relationships, largely via M&A route — over the last 5–6 years, 8–9 emerging biotech customers were acquired by big pharma and Anthem lost none of those programs, retaining a larger wallet share; 2 big pharma customers came in directly.
• Biotech funding revival a "mixed bag" — better RFP/RFQ inflow over the last quarter, but geopolitical uncertainty is keeping clients uneasy; 100+ projects with biotechs, and management is "hopeful" many succeed and become acquisition targets (typically at Phase 3, on strong data, or upon approval).

Rs.1,200 Cr Unit 4 Build-Out; White Spaces in Biologics and Oligos

• Capex guidance intact at ~Rs.1,200 Cr over FY 2026-2027–FY 2027-2028 — largely for Unit 4, a 30-acre facility sized equivalent to Units 1, 2 and 3 combined in Phase 1; commissioning expected around March 2028 (FY 2027-2028) with ramp-up time required thereafter.
• Post-FY28 capex guidance deferred — Phase 2 will be equivalent in size to Phase 1; formal guidance awaits board approval, though management said it is "fair to assume" numbers will be in a similar range; at least 30–35% of post-FY28 capex is indicated toward biology (fermentation), the rest in chemistry.
• White-space capabilities over the next 4–5 years — Anthem will ramp up biologics manufacturing and add drug product (biologics fill-finish) beyond its drug-substance-only footprint; confirmed white-space modalities are biologics, oncology, oligonucleotides and peptides, with oligo investment lined up in Unit 4 and cybersecurity cited as a big investment focus.
• New tech (peptides, ADCs, oligos, RNAi) contribution to FY31 not predicted — CFO noted a 10+ year journey since 2014-15, with commercial-scale capacities set up; how programs commercialize over 2027-2031 — "time will only tell."
• Asset turns at ~1.2–1.3x, aspiring to ~1.5x — the historical level is expected to be reached over FY 2027-2028 as utilization improves; reaching 1.5x will take a longer-term horizon given Unit 4 commissioning and approval timelines.
• Capex philosophy guided by customer pipelines — CEO said predicting which modalities become big five years from now is "a very hard call," so facility investments follow what customers are working on.

Backward Integration, US GTM via Davos, FY27 Targets On Track

• Backward integration as a moat — Anthem is almost always self-sufficient in enzymes/biocatalysts via its own fermentation-based solutions as programs mature; management cited historically "whimsical" supply chains outside the country and competitive cost of goods as reasons for in-house manufacturing.
• US go-to-market runs through Davos — a 50-year-old US partnership giving Anthem experienced feet-on-ground and near day-one customer access; Anthem Bangalore handles day-to-day customer contact while Davos covers the commercial side and supports small biotechs with logistics, customs and documentation.
• AI seen as "the real deal" though the "great unknown" — management expects more molecules to emerge from AI discovery pipelines, which it explicitly linked to more productization and chemistry work for companies like Anthem.
• Lateral/second-source contracts: traction but no mass switch yet — CEO said a switch "will happen" but qualification/ramp-up is inherently slow; being qualified as an approved second supplier positions Anthem for quick ramp-up if an incumbent falters.
• Full-year FY 2026-2027 commitments reaffirmed — CEO characterized Q2 as a "very good quarter," said investments, expansions and required regulatory approvals are all on track, and expressed confidence of "happy news to report" at the end of Q3 FY 2026-2027.